• / Free eNewsletters & Magazine
  • / My Account
Home>Alexion-Synageva Deal Shows Lure of Rare-Disease Drugs -- 3rd Update

Alexion-Synageva Deal Shows Lure of Rare-Disease Drugs -- 3rd Update

3party Content

Wed, 6 May 2015

By Peter Loftus, Jonathan D. Rockoff and Maureen Farrell The huge premium drug maker Alexion Pharmaceuticals Inc. is paying for Synageva BioPharma Corp8.4 billion, or more than double Synageva's market value--shows how hot the market has become for rare-disease drugs, which command huge prices and
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.